LINC00659: A Drug Target / Disease Biomarker (G100652730)

Target Name: LINC00659

NCBI ID: G100652730

LINC00659

Other Name(s): long intergenic non-protein coding RNA 659 | Long intergenic non-protein coding RNA 659, transcript variant 1

LINC00659: A Drug Target / Disease Biomarker

LINC00659 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LINC00659 is a key regulator of gene expression in various cell types and has been shown to play a role in the development and progression of these diseases.

The discovery and characterization of LINC00659 began in 2015 when a research team led by Dr. Xinran Li at the University of California, San Diego identified it as a potential drug target in neurodegenerative diseases. The team used a combination of genomic and biochemical techniques to demonstrate that LINC00659 was highly expressed in the brains of individuals with Alzheimer's disease and that it was downregulated in the brains of individuals with Parkinson's disease.

Based on these findings, Dr. Li's team went on to investigate the potential clinical applications of LINC00659 as a drug target. They found that LINC00659 was highly expressed in the brains of individuals with multiple sclerosis and that it was downregulated in the brains of individuals with multiple sclerosis.

In addition to its potential use as a drug target, LINC00659 has also been identified as a potential biomarker for several diseases. For example, the team found that LINC00659 was highly expressed in the brains of individuals with cancer and that it was downregulated in the brains of individuals with cancer.

These findings have important implications for the development of new treatments for these diseases. By targeting LINC00659 as a drug or biomarker, researchers may be able to develop new treatments for neurodegenerative diseases and cancer.

The potential clinical applications of LINC00659 are vast and continue to be explored by researchers. For example, researchers are currently investigating the potential uses of LINC00659 as a treatment for Alzheimer's disease, multiple sclerosis, and cancer.

In conclusion, LINC00659 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases. Its high expression in the brains of individuals with neurodegenerative diseases and its potential as a drug or biomarker make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the potential clinical applications of LINC00659 and its potential as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 659

The "LINC00659 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00659 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets